title: Ankylosing spondylitis-related secondary amyloidosis responded well to etanercept: a report of three patients.
abstract: Secondary (AA) amyloidosis is one of the most significant complications of ankylosing spondylitis (AS) that frequently leads to proteinuria and renal dysfunction. Anti-tumor necrosis factor alpha (anti-TNF) agents are promising in inducing clinical remission by suppressing systemic inflammation in AA amyloidosis. We report three cases with AS-related AA amyloidosis that responded well to etanercept therapy. Despite treatment with disease modifying anti-rheumatic drugs, all three patients had active AS, marked proteinuria, impaired renal function, and low serum albumin level. During 1-year treatment with etanercept, all patients experienced gradual improvement in all of these parameters.
authors.affiliation: Section of Rheumatology, Department of Medicine, Ege University School of Medicine, Bornova, Izmir, Turkey. senolkobak@yahoo.com.|, Suvari cad. 48/3, Bornova, Izmir, Turkey. senolkobak@yahoo.com.
authors.forename: Senol
authors.initials: S
authors.lastname: Kobak
authors.affiliation: Section of Rheumatology, Department of Medicine, Ege University School of Medicine, Bornova, Izmir, Turkey.
authors.forename: Fahrettin
authors.initials: F
authors.lastname: Oksel
authors.affiliation: Section of Rheumatology, Department of Medicine, Ege University School of Medicine, Bornova, Izmir, Turkey.
authors.forename: Yasemin
authors.initials: Y
authors.lastname: Kabasakal
authors.affiliation: Section of Rheumatology, Department of Medicine, Ege University School of Medicine, Bornova, Izmir, Turkey.
authors.forename: Eker
authors.initials: E
authors.lastname: Doganavsargil
mesh_terms: D000686:Amyloidosis / Q000150:complications* / Q000188:drug therapy; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D000068800:Etanercept; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use*; D012447:Sacrum; D013167:Spondylitis, Ankylosing / Q000188:drug therapy / Q000209:etiology*; D014409:Tumor Necrosis Factor-alpha
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D007074:Immunoglobulin G; D018124:Receptors, Tumor Necrosis Factor; D014409:Tumor Necrosis Factor-alpha; D000068800:Etanercept